Sugi Predict

Sugi Predict / Compounds / SCHEMBL3129135

SCHEMBL3129135

SCHEMBL3129135

O=C1CCCCc2occc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 3/20 0.39
▸ POLB P06746 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ MAPT P10636 3/20 0.39
▸ PKM P14618 1/20 0.39
▸ MAOA P21397 2/20 0.38
▸ MAOB P27338 2/20 0.38
▸ CYP2A6 P11509 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.37
▸ TSHR P16473 1/20 0.37
▸ ALOX12 P18054 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ CYP19A1 P11511 2/20 0.35
▸ TBXAS1 P24557 2/20 0.35
▸ HSP90AA1 P07900 1/20 0.34
▸ PRKCI P41743 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL333300 0.96 MAPT (0.42) HSD17B10POLBGAAMAPTPKM
SCHEMBL9123557 0.70 TSHR (0.38) TSHRHSP90AA1
SCHEMBL20721261 0.70 TSHR (0.38) TSHRHSP90AA1
SCHEMBL20721152 0.70 MAPT (0.37) HSD17B10POLBGAAMAPTPKM
SCHEMBL13090140 0.70 MAPT (0.39) HSD17B10POLBGAAMAPTPKM
SCHEMBL28307991 0.70 ALDH1A1 (0.36) MAOAMAOBKDM4ETSHRALDH1A1
SCHEMBL12180626 0.70 MAPT (0.39) HSD17B10POLBGAAMAPTPKM
SCHEMBL29420761 0.69 TRIM24 (0.37) CYP2A6ALDH1A1MEN1KMT2A
SCHEMBL9865613 0.68 ALDH1A1 (0.34) MAOAMAOBCYP2A6ALDH1A1PRKCI
SCHEMBL10736420 0.68 HTR2C (0.33) HSD17B10POLBGAAKDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466800-B2 N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4, 5, 6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS) ZOMAGEN BIOSCIENCES LTD (US) 2025-11-11 — — US disclosed
EP-3999496-B1 N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4,5,6,7-TETRAHYDROBENZOFURAN-2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) ZOMAGEN BIOSCIENCES LTD (US) 2024-12-18 — — EP disclosed
US-20240400501-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF ALLERGAN, INC. 2024-12-05 — — US disclosed
CN-114555571-B N- ((1, 2,3,5,6, 7-hexahydro-s-indacen-4-yl) carbamoyl) -4,5,6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives as NLRP3 modulators 祖玛珍生物科学有限公司 2024-08-27 — — CN disclosed
US-20220402866-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF ALLERGAN, INC. 2022-12-22 — — US disclosed
US-20220402866-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF ALLERGAN, INC. 2022-12-22 — — US disclosed
US-20220396559-A1 N-((1,2,3.5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4, 5, 6, 7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) ZOMAGEN BIOSCIENCES LTD 2022-12-15 — — US disclosed
US-20220396559-A1 N-((1,2,3.5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4, 5, 6, 7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) ZOMAGEN BIOSCIENCES LTD 2022-12-15 — — US disclosed
CN-114555571-A N- ((1,2,3,5,6, 7-hexahydro-s-indacen-4-yl) carbamoyl) -4,5,6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of Multiple Sclerosis (MS) 祖玛珍生物科学有限公司 2022-05-27 — — CN disclosed
EP-3999496-A1 N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4,5,6,7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) Zomagen Biosciences Ltd (US) 2022-05-25 — — EP disclosed
US-11208377-B2 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof ALLERGAN, INC. (US) 2021-12-28 — — US disclosed
WO-2021009566-A1 N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4,5,6,7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) ZOMAGEN BIOSCIENCES LTD (US) 2021-01-21 — — WO disclosed
WO-2021009566-A1 N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4,5,6,7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) ZOMAGEN BIOSCIENCES LTD (US) 2021-01-21 — — WO disclosed
EP-3668832-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF Allergan, Inc. (US) 2020-06-24 — — EP disclosed
CN-111225900-A 3, 4-disubstituted 3-cyclobutene-1, 2-diones and their use 阿勒根公司 2020-06-02 — — CN disclosed
WO-2019036374-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF ALLERGAN, INC. (US) 2019-02-21 — — WO disclosed
WO-2019036374-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF ALLERGAN, INC. (US) 2019-02-21 — — WO disclosed
US-20190047947-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF ALLERGAN, INC. 2019-02-14 — — US disclosed
US-8546410-B2 Heteroaryl-fused macrocyclic pyrimidine derivatives ABBVIE INC. (US) 2013-10-01 — — US disclosed
US-20100004256-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2010-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400501-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF IL17A, TSLP, SSB HSD17B10 153/4885POLB 2098/4885GAA 3569/4885
US-11208377-B2 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof IL17A, TSLP, SSB HSD17B10 153/4885POLB 2098/4885GAA 3569/4885
US-12466800-B2 N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4, 5, 6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS) FFAR3, NLRP3, NOD1 HSD17B10 1308/4885POLB 4828/4885GAA 4073/4885
US-20100004256-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES CDK2, DPYD, CCNB1 HSD17B10 2282/4885POLB 128/4885GAA 1155/4885
US-20220402866-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF IL17A, TSLP, SSB HSD17B10 153/4885POLB 2098/4885GAA 3569/4885
US-20190047947-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF IL17A, TSLP, SSB HSD17B10 153/4885POLB 2098/4885GAA 3569/4885
US-20220396559-A1 N-((1,2,3.5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4, 5, 6, 7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) GLS2, FFAR3, FABP1 HSD17B10 1341/4885POLB 4535/4885GAA 4223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.